EP
KROS icon

Essential Partners’s Keros Therapeutics KROS Stock Holding History

Essential Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2K Buy
206
+75
+57% +$835 ﹤0.01% 1933
2026
Q1 		$1.45K Sell
131
-52
-28% -$803 ﹤0.01% 2115
2025
Q4 		$3.73K Sell
183
-759
-81% -$13.3K ﹤0.01% 1546
2025
Q3 		$14.9K Buy
942
+811
+619% +$12K ﹤0.01% 1011
2025
Q2 		$1.75K Buy
+131
New +$1.77K ﹤0.01% 1350

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Essential Partners's KROS Position: Q2 2026 in Review

Essential Partners increased its Keros Therapeutics (KROS) stake by 57% in Q2 2026, buying an estimated $835 and bringing the position to 206 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

Essential Partners first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $14.9K in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Essential Partners held 206 shares of Keros Therapeutics worth $2.2K as of Q2 2026.
  • Essential Partners bought 75 Keros Therapeutics shares in Q2 2026, an estimated $835.
  • Keros Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1933 holding.
  • Essential Partners first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Keros Therapeutics position peaked at $14.9K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.